# Ventyx Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ventyx-biosciences

- Industry: Biotechnology
- Headquarters: US
- Website: www.ventyxbio.com
- Total disclosed funding: $165M
- Latest round: Series B (Sep 9, 2021)
- Investors on record: 14

## About

Based in California, US, and founded in 2019 by founder Raju Mohan, Ventyx Biosciences, Inc. operates as a clinical-stage biotechnology company. In March 2024, Ventyx Biosciences, Inc. raised USD 100 million in PIPE funding led by investor Farallon Capital Management, with participation from other investors Cormorant Asset Management, Redmile Group, and Surveyor Capital.  As part of the transaction, the company agreed to sell 11.17 million shares of common stock in a private placement for USD 100 million at USD 8.95 per share.The company got listed on the Nasdaq Global Select Market under the ticker symbol VTY.

Ventyx Biosciences, Inc. is a developer of immunology drugs that offers programs such as SP1P1R, TYK2, NLRPR, cGAS, Gasdermin D. The company's clinical stage pipeline includes: VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of autoimmune diseases; VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis; and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.

The company will use the March 2024 funding for advancing clinical and preclinical program developments, expanding research activities, and supporting general corporate operations.

## Funding rounds

- Series B, Sep 9, 2021, $51M — OrbiMed Advisors, Vivo Capital, Qiming Venture Partners, Wellington Management, Third Point, Surveyor Capital, LP Advisers LLC, VenBio, RTW Investments, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Logos Capital
- Series A, Jul 16, 2021, $57M — OrbiMed Advisors, Vivo Capital, Qiming Venture Partners, Wellington Management, Third Point, New Science Ventures, VenBio, RTW Investments, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Surveyor Capital, Logos Capital
- Series A, Mar 15, 2021, $57M — OrbiMed Advisors, Vivo Capital, Qiming Venture Partners, Wellington Management, Third Point, New Science Ventures, VenBio, RTW Investments, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Surveyor Capital, Logos Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A, Series B
- Third Point (https://capitalatlas.ai/funds/third-point) — Series A, Series B
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series A, Series B
- Janus Henderson Investors — Series A, Series B
- Surveyor Capital — Series A, Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A, Series B
- LP Advisers LLC — Series B